生物
启动(农业)
免疫
背景(考古学)
效应器
免疫系统
T细胞
树突状细胞
癌症免疫疗法
免疫学
获得性免疫系统
癌症
免疫疗法
抗原
癌症研究
细胞生物学
遗传学
古生物学
发芽
植物
作者
Mikaël J. Pittet,Mauro Di Pilato,Christopher Garris,Thorsten R. Mempel
出处
期刊:Immunity
[Elsevier]
日期:2023-10-01
卷期号:56 (10): 2218-2230
被引量:13
标识
DOI:10.1016/j.immuni.2023.08.014
摘要
In cancer patients, dendritic cells (DCs) in tumor-draining lymph nodes can present antigens to naive T cells in ways that break immunological tolerance. The clonally expanded progeny of primed T cells are further regulated by DCs at tumor sites. Intratumoral DCs can both provide survival signals to and drive effector differentiation of incoming T cells, thereby locally enhancing antitumor immunity; however, the paucity of intratumoral DCs or their expression of immunoregulatory molecules often limits antitumor T cell responses. Here, we review the current understanding of DC-T cell interactions at both priming and effector sites of immune responses. We place emerging insights into DC functions in tumor immunity in the context of DC development, ontogeny, and functions in other settings and propose that DCs control at least two T cell-associated checkpoints of the cancer immunity cycle. Our understanding of both checkpoints has implications for the development of new approaches to cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI